ReviewFrontiers in cellular and infection microbiology2022
Current and future perspectives for
Review in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Role of probiotic as adjuvant in treating various infections: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- The effects of probiotics supplementation on Helicobacter pylori standard treatment: an umbrella review of systematic reviews with meta-analyses.Scientific reports · 2024Pooled it
- Pooled it
- The effect of Saccharomyces boulardii supplementation on Helicobacter pylori eradication in children: a systematic review and meta-analysis of Randomized controlled trials.BMC infectious diseases · 2023Pooled it
- AdjuvantMicrobiology spectrum · 2026Trial
- Levofloxacin versus moxifloxacin in nitazoxanide-based quadruple therapy as a first-line treatment for Helicobacter pylori infection: NILE, a randomized, comparative, multicenter study.Scientific reports · 2026Trial
- Saccharomyces boulardii combined with triple therapy alter the microbiota in the eradication of Helicobacter pylori infection.Scientific reports · 2024Trial
- Evaluation of efficacy and safety ofFrontiers in immunology · 2024Trial
- Efficacy and safety of live combined Bacillus subtilis and Enterococcus faecium in patients with Helicobacter pylori infection: A meta-analysis of randomized controlled trials.Clinics (Sao Paulo, Brazil) · 2026Review
- Gastric Microbiota Dysbiosis and Microbiome-Based Interventions in Chronic Atrophic Gastritis.Nutrients · 2026Review
- Probiotics and Diet Modifications: A Holistic Approach to Tackling Helicobacter pylori with the Help of the Gut Microbiota.Probiotics and antimicrobial proteins · 2026Review
- Antimicrobial effects of Bacillus safensis BS05 cell free supernatant against Campylobacter jejuni and its probiotic evaluation.BMC microbiology · 2026Article
- Screening, Characterization, and Mode of Action of Three Lactic Acid Bacteria Against Helicobacter pylori.Probiotics and antimicrobial proteins · 2026Article
- Improving Helicobacter pylori Treatment Standards: A Quality Improvement Project Against Maastricht VI Guidelines.Cureus · 2025Article
- Article
- An AI-Designed Antibody-Engineered Probiotic Therapy Targeting Urease to CombatMicroorganisms · 2025Article
- Harnessing dual-channel probiotics to synergistically correct intestinal and vaginal dysbiosis after antibiotic disruption.NPJ biofilms and microbiomes · 2025Article
- Hydrogel-Transformable Probiotic Powder for Targeted Eradication of Helicobacter pylori with Enhanced Gastric Mucosal Repair and Microbiota Preservation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Green Chemistry Within the Circular Bioeconomy to Harness Chestnut Burr Extract's Synergistic Antimicrobial Activity AgainstMolecules (Basel, Switzerland) · 2025Article
- Non-antibiotic therapies for multidrug-resistant gastrointestinal infections: an overview of the use of probiotics, natural compounds, and bacteriophages.Frontiers in antibiotics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.